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INTRODUCTION 
 Colorectal cancer ranks fourth among the most common cancer in men 
and third among most common cancer in women. According  to a report in 
2008, it accounts for 9.4% of all cancers.(1) Colorectal cancer stands second in 
the leading cause of cancer mortality.(2)Every year, about one million new cases 
were diagnosed.(1) 
 Comparatively, countries like Australia, New Zealand, North America 
and Japan have highest annual incidence rates.(2)Developing countries like 
Africa, India and other parts of South east Asia have low annual incidence 
rates.(1)In India, incidence is about 7/100000.(34) 
 Both endogenous (constitutional) and exogenous (environmental) factors 
contribute to the risk of colorectal carcinomas.(1) Colorectal carcinoma mainly 
affects late middle aged and elderly individuals.(1)Most common symptoms of 
patients with colorectal carcinoma are abdominal pain, change in bowel habits, 
and hematochezia.(2) 
 Surgical resection is the main treatment of choice for colorectal 
carcinomas. The need for adjuvant therapy depends on further staging of disease 
by pathological assessment of resected specimen.(1) 
 The proto-oncogene HER2/neu is situated in chromosome 17q. 
HER2/neu plays an important role in controlling normal cell growth, 
differentiation and motility through the activation of transmembrane tyrosine 
kinase growth factor receptor encoded by it. Dysregulation of these pathways 
occur in cancer cells leading to overexpression of HER2/neu. Thus it results in 
tumor cell growth and migration.(5) 
 Monoclonal antibody therapy like trastuzumab  can be used for the 
colorectal carcinoma patients with HER2/neu overexpression.(5) 
 In this retrospective study, age, sex and site distribution of colorectal 
carcinomas are analysed. The present study also correlates HER2/neu 
expression with histological grades of colorectal carcinomas. 
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AIM OF THE STUDY 
 To analyse age, sex and site distribution of colorectal carcinomas. 
 To study the histopathological features of colorectal carcinomas. 
 To determine the level of expression of HER2/neu in colorectal 
carcinomas. 
 To correlate the level of HER2/neu expression with various histological 
grades of colorectal carcinoma. 
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MATERIALS AND METHODS 
  Fifty cases of colorectal carcinomas were diagnosed in our pathology 
department, Thanjavur Medical College during period of January 2016 to June 
2017.  
 Study design : Longitudinal retrospective study 
 Study period : January 2016 to June 2017. 
 Sample  : A total of 50 colectomy specimens received  
     from General surgery and Surgical     
    Gastroenterology department of Thanjavur                 
Medical College. 
Inclusion criteria 
 All cases that are diagnosed as colorectal carcinomas from resected 
colectomy specimen were included in the study. 
Exclusion criteria 
 1.  Colonoscopic biopsies 
 2. Cases with poor clinical history. 
Method of data collection: 
 All the 50 cases included in the present study were evaluated for the 
above mentioned criteria. 
 All information regarding age, sex, clinical presentation and colonoscopic 
findings were collected. 
 All hemicolectomy / pancolectomy/ abdominoperineal resection / low 
anterior resection specimens of colorectal carcinomas were fixed in 10% neutral 
buffered formalin in toto. Specimen were grossed and macroscopic features are 
noted. Tissue bits were taken from selected areas of tumours in resected 
specimens. After routine tissue processing , 4-5 micron thickness sections were 
taken and stained with routine hematoxylin and eosin stain for histopathological 
examination. (Appendix 1) 
 Histopathological examination was done to assess the grade and extent of 
tumour invasion. 
 For colorectal carcinoma, staging was done based on TNM staging. 
HER2/neu Immunohistochemistry 
 Among 50 cases of colorectal carcinoma, 25 cases were selected for 
evaluating the level of HER2/neu expression. Sections of 4micron thickness 
were taken from paraffin embedded blocks after routine tissue processing. 
Using advanced polymer staining system, these sections of colorectal 
carcinomas were stained with antibody directed against HER2/neu. 
 Immunohistochemical staining was done according to protocol 
(Appendix 2). These Immunohistochemical slides were assessed for percentage 
of tumor cells that have stained membranous positivity and also the intensity of 
staining is noted. 
Method of scoring (6,7) 
 0 - No staining at all or membrane staining in <10% of tumour  
 cells. 
 1+ - Faint / barely perceptible membrane staining in >10% of  
 tumour cells. 
 2+ - Weak to moderate staining of entire membrane in >10% of  
 tumour cells. 
 3+ - Strong staining of entire membrane in >10% of tumour   
 cells. 
   Staining score of 2+ and 3 +  considered as positive (6,7). 
 HER2/neu expression in colorectal carcinomas were correlated with its 
histological grades and statistical analysis was performed based on it. Statistical 
analysis was done using Fishers exact test. p value less than 0.05 (p<0.05) was 
taken to indicate statistical significance. 
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REVIEW OF LITERATURE 
 Colorectal cancer is a major world wide health problem (2). Based on 
estimation given by GLOBOCAN Project in 2008, about 1,235,108 colorectal 
cancer cases were registered worldwide and it accounts about 609, 051 deaths 
globally(5). Its worldwide incidence rate is about 2% annually (8). In 2009, 
according to U.S.Surveillance, Epidemiology and end results (SEER) program 
statistics, colonic carcinoma had an incidence of 30.45 per 100,000 and rectal 
carcinoma had an incidence of 12.16 per 100,000(1). In United States, lifetime 
risk for developing colorectal carcinoma in both males and females estimated to 
be 6% (2). From 1990 to 2012, incidence of colorectal tumours increases by 
about 200,000 new cases per year.(9) 
Anatomy of Large Intestine (3) 
 The extend of large intestine is from ileocaecal junction to anus. It 
measures about 1.5 metre long. The parts of large intestine are caecum, 
ascending colon, transverse colon, descending colon, sigmoid colon,rectum and 
anal canal. About 2 cm below the ileocaecal orifice , worm - like diverticulum 
called vermiform appendix arises from the posteromedial wall of the caecum. 
 
 
 
Histology 
 The large intestine is made up of four layers 
1) Mucosa 
 Mucosa is further divided into epithelium, lamina propria and muscularis 
mucosa. 
2) Submucosa 
3)Muscularis propria 
4) Serosa 
 The surface epithelium is lined by columnar cells into which the crypts 
open. In addition,it also contains goblet cells, endocrine cells and occasional 
paneth cells. Follicle associated epithelial cells or ‘M’ cells (M for microfold or 
membrane cells) are cells that lie in the epithelium overlying the lymphoid 
follicles of lamina propria. 
 Columnar cells are absorptive with striated border. These cells play an 
important role in the absorption of water and electrolytes from intestinal 
contents. 
 The main function of goblet cells is synthesis and secretion of mucin 
granules. Paneth cells may be seen occasionally in caecum, proximal right 
colon. Its major function is to secrete lysozyme and epidermal growth factor. 
 Lamina propria contains tubular glands which is formed by deep crypt 
epithelium. These glands are surrounded by lymphoid follicles. Submucosa 
contains loose connective tissue and submucosal plexus of Meissner. 
 Muscularis propria consists of inner circular layer and outer longitudinal 
layer of  smooth muscle. Myenteric plexus of Auerbach lies between these two 
muscle layers. Outer longitudinal layer is collected to form three  thick bands 
called Taenia coli. In rectum, taenia coli is absent and it contains a complete 
longitudinal muscle coat. 
 Serosa is absent over posterior aspect of ascending and descending 
colon.Also most of the rectum is devoid of serosa except front and sides of 
upper one-third and front of middle third. 
Etiology (1,2,9) 
 Both environmental and genetic factors play an important role. 
 Modifiable risk factors for colorectal carcinoma includes obesity, red 
meat, smoking, alcohol. Other risk factors are inflammatory bowel 
disease, oral contraceptive use, high caloric intake. 
 Obesity is one of the risk factor for colorectal carcinoma. This may be 
due to increased serum insulin production which inturn causes cellular 
proliferation in intestine. 
 Protective factors for colorectal carcinoma includes high calcium intake, 
folate intake, selenium intake, dietary fiber intake. 
 According to Nurses Health study report, women who consumed redmeat 
have 2.5 fold increase risk for developing colorectal cancers than the 
women who do not consume. 
 High fat diet results in bile acid production which inturn stimulates 
colonic epithelial proliferation thus resulting in tumour production. 
 Dietary Fibre plays a protective role by luminal dilution and binding of 
toxic substances, inhibition of carcinogens due to decreased colonic pH, 
less mucosal contact by fecal mutagens by decreasing colonic transit 
time. 
 Short chain fatty acids are produced by fermentation of dietary fibres by 
anaerobic organisms. These fatty acids increases fecal acidity thereby 
inhibiting carcinogen and bile acid metabolism. 
 There is a risk of colorectal carcinoma in patients who undergone 
cholecystectomy and gastrectomy, probably due to increased bile acids 
which inturn leads to colonic epithelial proliferation. 
 Vitamin A, Beta - carotene and vitamin E are protective due to its 
antioxidant properties. 
 According to a study, vitamin D and calcium intake proved to be 
protective against colorectal carcinoma. These agents form insoluble 
calcium soap in combination with bile acids or fatty acids, thus mucosal 
damage was prevented. 
 The frequency of rectal carcinoma was more frequent in persons with 
heavy beer drinking. 
 If there is a family history of colorectal carcinoma, other family members 
had 21% life time risk for developing colorectal cancer. 
 Genetic syndrome that predispose to colorectal carcinoma include 
familial adenomatous polyposis, juvenile polyposis syndrome, cowden 
syndrome, serrated polyposis, heriditary polyposis colorectal cancer etc. 
 Colorectal carcinoma due to genetic factors constitutes about 20%. 
 
 
 
 
 
 
 
 
 
 
 
 
Pathogenesis (4) 
 There is heterogenous groups of molecular events behind the 
pathogenesis of colonic carcinoma which includes genetic and epigenetic 
abnormalities. Two genetic pathways mainly associated are APC/ß - catenin 
pathway and microsatellite instability pathway. 
 About 80% of colonic tumours (sporadic) are due to classic adenoma - 
carcinoma sequence. This is caused by APC mutation in the earlier stage of 
neoplastic process. Mutation or epigenetic events causes functional inactivation 
of two copies of APC gene resulting in development of adenomas. APC 
negatively regulates ß - catenin by binding and promoting its degradation. If 
APC function is lost, accumulation of ß- catenin results. This inturn leads to 
formation of DNA-binding factor TCF complex and activation of gene 
transcription (MYC and Cyclin D1). These molecular events finally results in 
proliferation. 
 In many colonic tumours, instead of APC mutations, ß-catenin mutations 
results in same impact by preventing degradation caused by APC. In addition to 
these mutations, KRAS mutation also causes tumour growth by preventing 
apoptosis. Mutations in genes encoding SMAD2 and SMAD4 (tumour 
suppressor genes) also results in neoplastic growth since they are associated 
with TGF-ß signaling. Normal  function of TGF-ß is cell cycle inhibition. Thus 
mutation of these genes leads to uncontrolled cell growth. 
 TP53 is a tumour suppressor gene. Its mutation was reported in about 
80% colonic tumours. In adenomas, TP53 mutations are uncommon. This 
suggests that TP53 mutations can occur at later stages of carcinogenesis. 
 The main hallmark behind APC/ß-catenin pathway was chromosomal 
instability. 
 Microsatellite instability refers to accumulation of mutations in 
microsatellite repeats in patients having DNA mismatch repair deficiency. They 
are known as MSI high (MSI -H) tumours. Cell growth is regulated by certain 
microsatellite sequences which are situated in coding or promoter regions of 
genes eg.genes encoding type II TGF-ß receptor and BAX protein. The function 
of TGF-ß is to inhibit cell growth so its receptor mutation results in unrestrained 
growth. Loss of proapoptotic protein BAX increase cell proliferation due to 
apoptotic inhibition. 
 CPG island hypermethylation phenotype (CIMP) was demonstrated in 
colonic tumours with microsatellite instability. Many of these tumours harbor 
hypermethylation of promoter region MLH 1 and reduced repair function. 
 BRAF mutations are frequently seen in these tumours. Thus, signature of 
microsatellite instability pathway of carcinogenesis was microsatellite 
instability, mutation in BRAF and MLH 1 methylation. 
 Colonic tumours with TP53 mutations lack CPG island methylator 
phenotype. Tumours with microsatellite instability and CPG island 
hypermethylation phenotype are commonly situated in proximal colon. 
COLORECTAL CARCINOMA 
WHO CLASSIFICATION OF TUMOURS OF COLON AND RECTUM 
Epithelial tumours Types 
Adenoma 
Tubular 
villous  
Tubulovillous 
Serrated 
Intraepithelial neoplasia 
(dysplasia) 
Low grade glandular intraepithelial neoplasia 
High grade glandular intraepithelial neoplasia 
Carcinoma 
Adenocarcinoma 
Mucinous adeno carcinoma 
Signet ring cell carcinoma 
Small cell carcinoma 
Squamous cell carcinoma 
Adenosquamous carcinoma 
Medullary carcinoma 
Undifferentiated carcinoma 
Carcinoid (well 
differentiated endocrine 
neoplasm) 
EC-cell, Serotonin - producing neoplasm 
L-cell, Glucagon - like peptide and PP/PYY 
producing tumour 
Others 
Mixed carcinoid-adeno 
carcinoma  
Others  
 
 
Non - Epithelial Tumours 
1. Lipoma 
2. Leiomyoma 
3. Gastrointestinal stromal tumour 
4. Leiomyosarcoma 
5. Angiosarcoma 
6. Kaposi Sarcoma 
7. Malignant melanoma 
8. Others 
Malignant lymphomas 
 Marginal zone lymphoma 
 Mantle cell lymphoma 
 Diffuse large B cell lymphoma 
 Burkitt lymphoma 
 Others 
Secondary Tumours 
Adenocarcinoma (1,10,11) 
 Adenocarcinoma constitutes about 85% of colorectal carcinomas. Among 
them, moderately to well differentiated are common. Prominent villous or 
papillary component can be seen in some tumours at the surface. It may 
penetrate all the bowel layers into pericolic fat and perineural spaces. Venous 
invasion can also be seen. 
 Based on degree of gland formation, it is divided into three grades. Grade 
I tumours constitutes about 15 to 20% of colorectal adenocarcinomas, grade II 
tumours constitutes about 60 to 70% and grade III tumours constitutes about 15 
to 20% of colorectal adenocarcinomas. Thus, grade I and II tumours are low 
grade tumours whereas grade III and undifferentiated carcinoma are high grade 
tumours. Colorectal carcinomas are termed as grade III if more than 50% of 
tumour composed of poorly differentiated component. 
 If the tumour cells are detached and migrated into the stroma at the 
advancing  edge of the tumour, it is termed as tumour budding. Histologically, 
tumour buds should composed of five tumour cells or less at the advancing edge 
of the tumour. 
 Mostly, grade I and II tumours are associated with greater degree of 
tumour budding. Tumour budding was associated with poorer prognosis. 
Mucinous adenocarcinoma(12) 
If tumour composed of more than 50% of mucin with tumour cells floating in 
pools of extracellular mucin, it is termed as mucinous adenocarcinoma.About 
15% of colorectal carcinoma are mucinous carcinomas and its most common 
location is rectum. Most of the microsatellite instability (MSI - H) carcinomas 
belong to this type. Mucinous carcinomas have higher incidence of extensive 
perirectal spread and involvement of lymph nodes than non-mucinous colorectal 
tumours. Prognosis is poor compared to conventional adenocarcinoma. 
 
Signet ring cell carcinoma(13) 
 It is also known as Linitis plastica type carcinoma. If a tumour contains 
more than 50% tumour cells with prominent intracytoplasmic mucin, it is 
termed as signet ring cell carcinoma. Grossly, it usually present as diffuse 
infiltration of wall. Young patients are commonly affected. MSI-H carcinomas 
constitutes about one third of cases. It is an aggressive tumour with bad 
prognosis. 
Small cell carcinoma(14) 
 Its histological features is similar to small cell carcinoma of lung. 
Commonest site is right colon. It has poor prognosis with lymph nodes and liver 
metastases at earlier stage. They express positivity for neuron specific 
enolase, synaptophysin, chromogranin and Leu-7. 
Squamous and adenosquamous carcinomas(15) 
 These are very rare tumours. They are commonly seen in patients with 
ulcerative colitis, schistosomiasis and pelvic irradiation. 
 The criteria that is essential to make the diagnosis of squamous or 
adenosquamous carcinoma of colorectum are  
1. There must be no other sites of squamous cancer in the body. 
2. There must be no involvement of cloacogenic or squamous lined mucosa. 
 
 
Medullary carcinoma(16) 
 Rare tumour among  colorectal tumours.  It is composed of neoplastic 
cells arranged in sheets with prominent lymphocytic infiltration. Medullary 
carcinomas are commonly situated in proximal colon with female 
preponderance. These tumours have good prognosis and lymph node metastasis 
is less compared to other tumours. Prognosis is better than poorly differentiated 
colorectal carcinomas. 
Undifferentiated Carcinoma(17) 
 Undifferentiated carcinomas are malignant epithelial tumours without any 
differentiation. They are different from poorly differentiated carcinomas since 
the later contains intracytoplasmic mucin. 
Carcinoids and Neuroendocrine Carcinoma(18) 
 These tumours are rare among colorectal carcinomas. They usually 
occurs in caecum and rectum. Conventional adenocarcinomas can show focal 
neuroendocrine differentiation. 
Serrated Adenocarcinoma(11) 
 Serrated adenocarcinoma was a recently proposed entity. It comprises 
7.5% of  all colorectal tumours. It accounts for about 10-15% of proximal 
colonic carcinomas with female preponderance. Serrated adenocarcinoma 
associated with MSI-L or MSS had worse prognosis than those that are 
associated with MSI-H. 
Histological features of serrated adenocarcinomas are 
1. Epithelium has a serrated pattern with no loss of polarity. Cells have 
abundant eosinophilic cytoplasm with bland or vesicular nuclei. 
2. Mucinous differentiation was found in 43% of these tumours. 
Histologically, these tumours composed of  mucin pools containing 
eosinophilic papillary rods and cell balls. They are different from 
classical mucinous carcinomas. 
3. Trabecular pattern was seen in poorly differentiated serrated 
adenocarcinomas. 
Micropapillary adenocarcinoma(11) 
 This is an aggressive tumour. Histologically, micropapillary 
adenocarcinoma composed of neoplastic cells in balls or clusters separated by 
cleft like spaces. The diagnosis of micropapillary adenocarcinoma requires the 
presence of atleast 5% tumour cells with micropapillary features. Lymph node 
metastasis is more frequent. 
Carcinoid tumour 
 Grossly, it may present as depressed plaque or polypoid lesion. EC-cell 
tumours are serotonin producing with histological features similar to its 
counterpart in jejunoileal region. L-cell tumours are glucagon like peptide and 
PP/PYY - producing tumours. L-cell tumours composed of predominant ribbon 
pattern (Type B) with admixture of tubular, acinar or irregular trabeculae with 
rosettes (Type C) and sometimes, areas of solid nests (Type A). In EC-cell 
tumours, type A structures are seen. 
Mesenchymal tumours 
 Mesenchymal tumours in large intestine are very rare. Common sites of 
lipoma are caecum and sigmoid colon. 
 Gastrointestinal stromal tumour (GIST) affects individuals between 6th 
and 8th decades. Malignant GIST are common in colorectum than benign ones. 
 Leiomyomas usually present as small polyps in colorectal region arising 
from muscularis mucosae. Vascular tumours like hemangiomas, 
lymphangiomas, hemangioendothelioma and angiosarcoma can be seen in 
colorectal region. 
Malignant Lymphoma 
 Frequency of lymphomas is less in large intestine.It accounts for 0.2% of 
colorectal tumours. Mostly older patients are affected. Common sites of 
malignant lymphoma in colorectal region are distal large intestine and rectum. 
Mucosa Associated Lymphoid Tissue type (MALT) is common lymphoma seen 
in colon. 
 Diffuse large B-cell lymphoma and  Burkitt lymphoma usually present as bulky 
masses with stricture and ulceration. Mantle cell lymphoma tend to form 
isolated mass or present as multiple polyps. MALT lymphomas may remain 
asymptomatic for prolonged periods but loco-regional  lymph nodes are 
frequently involved. Among these lymphomas, mantle cell lymphoma has an 
aggressive behavior since it presents at advanced stage with metastasis in 
spleen, mesenteric and peripheral lymph nodes. Often, bone marrow and 
peripheral blood involvement can also be made out. 
Grading  of Colorectal adenocarcinoma(1) 
Grade Descriptive nomenclature Criteria AJCC recommendation 
Gx Grade can not be assessed - - 
G1 Well differentiated 95% gland forming Low grade 
G2 Moderately differentiated 50% - 95% gland forming Low grade 
G3 Poorly differentiated <50% gland forming High grade 
G4 Undifferentiated 
No apparent 
gland 
formation 
High grade 
 
 
Staging of colorectal carcinoma 
 In colorectal carcinomas, tumour behaviour and outcome is mainly 
determined by anatomic extent of tumour spread. Pathologic evaluation helps in 
clinical management of patients and research purposes. It also helps in 
documentation of lesion in case of follow up studies. 
DUKE’S staging system (11) 
 In 1932, Dukes explained a staging system which is less complicated  
A Tumour confined to the intestinal wall 
B Tumour invading through the intestinal wall. 
C With lymph node(s) involvement 
C1 Only the regional lymph nodes are involved 
C2 Nodes at the point of mesenteric blood vessel ligature are involved 
D Distant metastasis 
 
ASTLER - COLLER STAGING SYSTEM (11) 
A Tumour limited to the mucosa 
B1 Tumour involving muscularis externa but not penetrating it. 
B2 Tumour penetrating through muscularis externa 
C1 Tumour confined to the bowel wall with regional lymph node metastases 
C2 Tumour penetrating through the wall with regional lymph node metastases 
D Distant Metastases 
 
Additional Staging 
Venous invasion (v) 
 V0  - No venous invasion 
 V1 - Microscopic venous invasion 
 V2 - Macroscopic venous invasion 
Lymphatic invasion (L) 
 L0 - No lymphatic vessel invasion 
 L1 - Lymphatic vessel invasion 
 TNM staging system was developed by the American Joint 
Communication on Cancer (AJCC). This staging system is based on 
 T - Degree of tumour invasion 
 N - Lymph node involvement status 
 M - Distant metastasis 
AJCC TNM STAGE CRITERIA (19, 20) 
Stage  0 Tis N0M0 Tis : Tumour confined to mucosa; cancer - in-situ 
Stage I T1N0M0 T1 : Tumour invades submucosa T2N0M0 T2 : Tumour invades muscularis propria 
Stage II A T3N0M0 T3 : Tumour invades subserosa or pericolic tissue 
Stage II B T4N0M0 
T4 : Tumour directly invades other organs or structures and /or perforates visceral peritoneum 
Stage III A T1-2N1M0 N1  : Metastasis to 1-3 regional lymph nodes Stage III B T3-4N1M0  
Stage III C Any TN2M0 N2 : Metastasis to 4 or more regional lymph nodes 
Stage IV Any T AnyN M1 M1  : Distant metastasis present  
HER2/neu 
 HER2/neu also called as ErbB-2, c-erbB2, HER-2. It belongs to the 
family of Human epidermal growth factor receptor (HER). There are many 
members of Human epidermal growth factor receptor like HER-1 (EGFR or 
ErbB1), HER-2, HER-3 (ErbB3) and HER-4 (ErbB4). 185 - KDa plasma 
membrane-bound tyrosine kinase receptor is situated on chromosome 17q21. 
This tyrosine kinase receptor is encoded by HER-2, which is a proto oncogene. 
Phosphoinositide-3-kinase, mitogen activated protein kinase (MAPK), 
phospholipase C and protein kinase C are activated when HER2/neu is 
stimulated by extracellular signals.  
 Thus it results in signal transduction and transcription (27). Thus it controls 
cellular proliferation and differentiation. It also inhibits apoptosis and tumour 
growth. It plays an important role in cell to cell and cell to stromal 
communication. Two copies of HER-2 gene present in all normal epithelial 
cells. HER2 receptors are expressed in low levels on the surface of cells. 
Carcinomas of  breast, ovary, colon, uterus, stomach, prostate and lung shows 
HER2/neu overexpression and its amplification. The expression of  HER2/neu 
in tumours of colorectal region varies from 0% to 83%.(6) 
 There are many methods to assess HER2/neu expression. 
Immunohistochemistry is commonly used.(23) 
 A Pappas et al (5) in his study, evaluated HER2/neu expression in 51 
colorectal carcinomas using Immunohistochemical technique. Among them,22 
cases were colonic carcinomas and 29 cases were rectal carcinomas. They found 
that 3.9% of colorectal carcinoma cases showed HER2/neu overexpression. 
According to this study, most of the tumours are grade 2 (84.3%) when 
compared to grade 1 and grade 3 tumours. No correlation was found between 
patient’s age, sex and clinicopathological details. The factors influencing 
HER2/neu expression are tissue fixation,primary antibody choice, antigen 
retrieval process, antigen dilution and time given for antigen retrieval and 
peroxidase reaction. There is disagreement between membranous and 
cytoplasmic staining since cytoplasmic staining of HER2/neu is noticed in more 
number of cases. This study considered only membranous positivity. 
 Manmeet Kaur Gill et al(8) performed a study in 20 colorectal carcinoma 
cases. In their study, metastasis was reported in 10 nodes (50%) and HER2 
expression was noticed in all ten nodes positive for metastasis. Out of ten 
remaining reactive nodes, HER2 expression was noticed in four cases. There 
was an association between HER2 staining and lymph nodes metastasis with a 
statistically significant p value 0.015. The difference in HER2/neu expression 
may be due to variation in tissue fixation, different patterns of HER2 scoring 
and varying IHC procedures. 
 Sadia Anwar et al (6) in his study of 100 colorectal tumours, observed that 
42% cases showed HER2 positivity. Among them, moderate membranous 
positivity (2+) was noticed in 28.5% (n=12) of conventional adenocarcinomas 
and 30.7% (n=8) mucinous carcinomas. Strong membranous positivity (3+) was 
observed in 52.3% (n=22) of conventional adenocarcinomas and 42.8% (n=6) of 
mucinous carcinoma cases. Signet ring cell carcinomas showed negative 
staining. There was an inverse association between HER2/neu score and 
histological grade with a significant statistical value p=0.001. Thus maximum 
HER2/neu overexpression noticed in low grade tumours than high grade 
tumours. There was no association between tumour histology, grade, age, sex, 
location and clinical presentation (p>0.05). 
 According to Essapen et al (51), 41% cases out of 170 cases of colorectal 
tumours showed strong positivity for HER2/neu immunohistochemistry. 
 An Na Seo et al (23) reported that (in cohort 1) out of 365 patients, 14 
cases (3.8%) had moderate membranous staining (2+) and 8 cases (2.2%) had 
strong membranous staining (3+) for HER2/neu. In cohort 2, out of 174 
advanced colorectal carcinoma patients, 5 cases (2.9%) had moderate 
membranous positivity (2+) and 5 cases (2.9%) showed strong membranous 
positivity (3+) for HER2/neu IHC. In cohort 1, 2.5% cases and in cohort 2, 
2.3% cases was detected with HER2 mRNA overtranscription.There was no 
correlation between HER2 expression with tumour infiltration, lymph node 
status, distant metastasis and perineural invasion (p>0.05). There was 
correlation between HER2 expression and tumour site (p=0.033) in cohort 1. 
There was no association between HER2 mRNA overtranscription with 
clinicopathological details except tumour site (p=0.001 in cohort 1, p=0.026 in 
cohort 2). There was correlation between HER2 gene amplification and tumour 
site. 
 Soo Kyung Nam et al(21) performed a study on 191 colorectal carcinoma 
patients in advanced stage with distant metastasis. They observed wild type 
KRAS mutation in 87 (45.5%) cases and KRAS mutation in 104 (54.5%) cases. 
Among them, mutation in codon 12 or 13 was noticed in 97 (93.3%) cases and 
codon 61 mutation noticed in 7 (6.7%) cases. 3.1% tumours was detected with 
BRAF mutations. PIK3CA mutations was detected in 13.1% (n=25). HER2 
gene amplification was observed in 8.4% (n=16) tumours by SISH analysis. 
Among 191 cases, 1.6% were MSI-H and 98.4% tumours were MSS/MSI-L. 
There was an association between PIK3CA mutations and KRAS mutations 
(p=0.020). HER2 amplification and mutation in BRAF were commonly noticed 
in KRAS wild type rather than mutant type. There was no correlation between 
MSI status and genetic alterations. Proximal colon was commonly affected by 
KRAS mutant tumours especially low grade tumours whereas distal colon was 
frequently involved by tumours with  HER2 amplifications. There was no 
correlation between PIK3CA mutations with MSI status or clinicopathologic 
variables. 
 Nathanson et al (30) studied HER2/neu expression in 139 cases of 
colorectal tumours and  among them, 5 cases (3.6%) had HER2/neu over 
expression and 4 cases (2.4%) showed HER2/neu gene amplification. There is 
no correlation between HER2/neu overexpression and gene amplification with 
clinicopathologic features or survival rate of patients. 
 Kavanagh et al (31) performed a study which included 132 colorectal 
cancer patients and observed that 9 cases (85%) expressed moderate 
membranous staining and 2 cases (2%) showed strongly positive staining for 
HER 2/neu immunohistochemistry. There was no association between sex, age, 
stage, grade, survival rate and recurrence. 
 A study by park et al (32) in 137 colorectal carcinoma patients showed 65 
cases (47.4%) with HER2/neu overexpression. Neither tumour grade nor staging 
were correlated with each other. They found that tumours with HER2/neu 
overexpression had increased recurrence rate. 
 According to Osako et al (33) in his study involving 146 colorectal cancer 
cases, 100 (68.5%) showed cytoplasmic staining and only 3 cases revealed 
membranous positivity for HER2/neu. 
          According to a study by Mckay et al(44), 81.8% tumours expressed 
HER2/neu. They studied HER2 expression in both primary as well as in 
metastatic tumours in lymph node. They finally concluded that there was no 
association between HER2 expression and lymph node metastases. 
          According to Cancer Genome Atlas(TCGA) Colorectal cancer project, 
7% cases had HER2 alterations, 5 cases had HER2 gene amplification. HER-2 
mutations and amplification were present in 3 cases.(25) 
 A study by Schuell et al(7) in 77 colorectal carcinoma cases showed 
HER2/neu positivity in 30% of cases, with moderate membranous positivity in 
1%  case and strong positivity in 3% cases, 26% cases with mild membranous 
positivity. There was no correlation between HER2/neu expression with 
survival rate and clinicopathological information. 
         According to Fanotto et al(27) ,HER2 amplification was found in distal 
carcinomas of colon more frequently when compared to proximal colonic 
carcinomas. 
 Won - Suk Lee et al (29) studied HER2/neu expression and KRAS status in 
94 colorectal carcinoma patients both in primary tumours as well as in 
metastatic lesions (lung or liver metastasis). Among them, 2.1% of cases 
showed strong membranous positivity by IHC whereas 10.1% cases showed 
expression in HER2 amplification(FISH). In one of these patients, HER2 
staining showed positivity in metastatic lesion but not in primary tumour. 64 
cases (68.1%) showed negativity for both HER2/neu Immunohistochemistry 
and FISH; Two cases showed positivity in both IHC and FISH and 7 cases 
(7.4%) showed equivocal results. 85.1% cases expressed HER2/neu protein 
expression in both primary and metastatic tumours. Two cases showed positive 
IHC staining in primary  tumour  but not in metastasis. There was no correlation 
between HER2 status and KRAS status (p=0.486). They observed that 87.2% of 
cases had KRAS mutations in both primary as well as in metastatic lesions. 
HER2/neu over expression was noticed in 5.3% (n=10) cases with KRAS 
mutations. 
 SD Richman et al (28) observed strong HER2 expression in 25 colorectal 
carcinoma patients with stage II - III tumours and 29 colorectal carcinoma 
patients with stage IV tumours. HER2 amplification by FISH was seen in 20 
colorectal carcinoma patients with stage II - III disease and 27 colorectal 
carcinoma patients with stage IV disease.There was correlation between 
HER2/neu expression and KRAS/BRAF WT tumours especially in tumours of 
stage IV. They proposed that MEK-AKT pathway was activated by HER2 
amplification in colorectal carcinoma. In RAS/RAF WT patients, HER2 
expression should be assessed to detect the response to the HER2 targeted 
therapy. 
 JinhuaTu et al (26) evaluated HER2/neu overexpression in 878 colorectal 
carcinoma specimens and found that out of 878 patients, 102 cases (11.6%) 
showed HER2 overexpression. Among them, strong positivity (3+) was 
observed in 25 cases and moderate membranous positivity (2+) was found in 77 
patients. According to this study, patients with stage 0, stage I and stage II 
disease showed more HER2 expression than stage III and stage IV patients. 
There was no correlation between HER2 overexpression and sex, age, tumour 
location, staging and lymph node status. Out of 102 cases with strong HER2 
membranous positivity, 25 cases (24.5%) showed positivity in HER2 gene 
amplification. Out of 77 cases with moderate HER2  positivity, only 5 
cases(6.5%) expressed positivity in HER2 gene amplification.  
 Antonacopoulou et al (35) in their study of 124 colorectal cancer patients 
found that 24.7% cases showed HER2/neu overexpression. They also evaluated 
EGFR and COX-2 levels by IHC. In 46 cases of colorectal cancers, reverse 
transcriptase PCR was used to assess mRNA levels. There was association 
between EGFR expression and mRNA (p<0.001). Also HER2 expression 
(p<0.004) and COX-2 expression (p<0.007) correlated with mRNA levels. 
There was no association between EGFR with tumour stage or grade. 
 Demirbas et al (36) observed HER2 expression in 44.3% of colorectal 
tumours  by IHC. Among these cases, most of the tumours are situated in 
rectum and they are above 5cm size. HER2/neu overexpression correlates with 
grade and vascular invasion. Tumours with lymphatic invasion showed more 
HER2 expression but it was not statistically significant. Tumours of Astler-
Coller stage C1 and C2 were frequently observed with HER2 and TP53 
overexpression. They demonstrated overexpression of HER2 and TP53 among 
moderately differentiated and poorly differentiated carcinomas. According to 
this study, there was an association between HER2 expression in colorectal 
carcinoma and its prognosis. 
 According to a study by Kruszewski et al (37), out of 202 colorectal 
carcinoma patients, 27% cases showed HER2/neu positivity. Among them, 
26.7% cases had membranous positivity and 66.3% cases had cytoplasmic 
positivity. Moderate positivity(2+) was observed in 32% cases and strong 
positivity(3+) was observed in 15% cases. No association was observed 
between HER2 expression and other variables like age, sex, site, tumour grade, 
histological variant, tumour stage. 
 Kim et al (38) in his study found that HER2/neu was overexpressed in 
0.5% of cases out of 185 patients with colorectal carcinoma. They also studied 
the expression of COX-2 and Ki-67 protein. 94.3% of cases expressed COX-2 
protein and 5.9% cases were found with Ki-67 expression. No correlation was 
found between HER2, COX-2, and Ki-67 expression. 
 Marx et al (39) studied HER-2 expression using tissue microarray (TMA) 
and found that out of 1851 patients, 2.7% patients showed overexpression of 
HER2/neu. There was no relationship among HER2 amplification with tumour 
site, grade, tumour histology and stage. 
 B Ingold Heppner et al (24) reported that among 1645 colorectal cancer 
cases, 53 cases expressed 1+ HER2/neu staining, 9 cases expressed 3+ strong 
positivity and 35 cases with equivocal result. They also evaluated HER2/neu 
status in lymph node metastases of these patients. They found (n=12) similar 
HER2/neu profile like that of their primary tumour. HER2/neu amplification 
was detected in 57.8% (n=26) cases. Among them, nine cases had strong 
positivity and 17 cases had moderate membranous positivity for HER2/neu 
IHC. There was an significant association between HER2 status and lymph 
node metastasis. There was no significant correlation between HER2 expression 
and clinicopathological variables. 
 Kafi SG et al (40) studied 69 cases with colonic adenocarcinoma and 
evaluated HER2/neu expression in them to find out the frequency and intensity 
of HER2/neu staining. Out of 69 cases, 34.1% cases showed membranous 
cytoplasmic staining. They observed that there was no association between 
HER2/neu expression with gender, location and variant of tumour. 
 Tavangar et al (41) studied 55 colorectal carcinoma patients and performed 
HER2/neu IHC. Significant correlation found between HER 2/neu over 
expression and advanced disease stage (p<0.05). Also size of tumour and 
HER2/neu over expression showed positive correlation (p<0.05). There is also 
positive correlation between tumour grade and HER2/neu expression (p<0.001). 
They observed that right colonic tumours constitutes 45.6% whereas left 
colorectal tumours constitutes 54.4%. In his study, mostly moderately 
differentiated and poorly differentiated carcinomas overexpressed HER2/neu. 
 Li et al (42) evaluated HER2/neu expression in 317 colorectal carcinoma 
specimens. Among them, 49 cases (15.5%) showed HER2/neu positivity with 
strong positivity in 7 cases. There was association between HER2/neu 
expression and tumour size (p<0.05). But there was no association with 
clinicopathological features. 
 According to a study by Lazaris et al (43), HER2/neu expression was 
found in 36% of cases and they reported it as a predictor of poor outcome. 
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OBSERVATION AND RESULTS 
 Histopathological examination of 50 cases of colorectal carcinoma were 
studied and staging was done based on TNM classification. The following are 
the results. 
Table -1 
Age presentation of colorectal carcinoma 
Age Male Female Total 
21 to 30 0 0 0 
31 to 40 3 3 6 
41 to 50 5 8 13 
51 to 60 8 7 15 
61 to 70 5 5 10 
71 to 80 6 0 6 
Total 27 23 50 
 
 From table no.1, it was evident that age of colorectal carcinoma patients 
range from 35 to 75 years. Males are more affected than females. 
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Table -2 
Clinical presentation of colorectal carcinoma 
 
Symptoms No of Cases Percentage 
Altered Bowel Habits 35 70% 
Abdominal Pain  20 40% 
Bleeding per rectum 15 30% 
Weight loss 8 16% 
Intestinal Obstruction 8 16% 
 
 Table No.2 shows that, the most common clinical presentation of 
colorectal carcinoma patients in our study was altered bowel habits (70%) and 
abdominal pain (40%). 
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Table - 3 
Colonoscopic findings of tumours of colorectal region 
Colonoscopic findings No. of cases Percentage 
Ulceroproliferative 37 74% 
Narrowing of Lumen 10 20% 
Polyp 3 6% 
Total 50 100% 
 
 Above table.3 shows that grossly, ulceroproliferative growth was the 
common macroscopic finding found in colorectal carcinomas. 
 
 
 
 
 
COLONOSCOPIC FINDINGS OF TUMOURS OF COLORECTAL REGION
74%
0%
10%
20%
30%
40%
50%
60%
70%
80%
Ulceroproliferative Narrowing of Lumen
CHART - 3 
20%
6%
Polyp
Ulceroproliferative
Narrowing of Lumen
Polyp
Table - 4 
Site distribution of colorectal carcinomas 
 
Site No.of cases Percentage Male Female Total 
Caecum 5 3 8 16% 
Ascending Colon 4 2 6 12% 
Hepatic Flexure 1 1 2 4% 
Transverse Colon 1 0 1 2% 
Descending Colon 0 0 0 0% 
Sigmoid Colon 4 4 8 16% 
Rectum 12 13 25 50% 
Total 27 23 50 100% 
 
 From table no.4, it was evident that the most common site affected by 
colorectal carcinomas was rectum (50%), followed by caecum (16%) and 
sigmoid colon (16%).  In both sexes, rectum was commonly affected in 
colorectal carcinoma. 
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Table - 5 
Correlation of site distribution of tumours of colorectal region with age 
Site 21-30 31-40 41-50 51-60 61-70 71-80 Total 
Caecum 0 3 1 3 1 0 8 
Ascending Colon 0 0 1 4 1 0 6 Hepatic Flexure 0 0 0 0 1 1 2 Transverse Colon 0 0 0 0 1 0 1 
Descending Colon 0 0 0 0 0 0 0 
Sigmoid Colon 0 0 2 4 1 1 8 Rectum 0 4 8 5 5 3 25 
Total 0 7 12 16 10 5 50 
 
 From above table no.5, it was evident that the most common site affected 
in all age groups was rectum. 
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Table - 6 
Size distribution of tumours of colorectal region 
Size No. of Cases 
Upto 5Cm 32 
6 - 10 Cm 14 
>10 Cm 4 
Total 50 
 
 In this study, most of the tumours of colorectal region are less than 5 cm 
in size.  
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Table - 7 
Correlation of size distribution of tumours of colorectal region with site 
Site Size Total upto 5 cm 6-10 cm >10cm Caecum 5 2 1 8 
Ascending Colon 4 2 0 6 
Hepatic Flexure 1 0 1 2 
Transverse Colon 0 0 1 1 
Descending Colon 0 0 0 0 
Sigmoid Colon 6 2 0 8 
Rectum 16 8 1 25 
Total 32 14 4 50 
 
 From table no.6&7, it was inferred that tumours less than 5cm size are 
more common in all the regions of large intestine. This was mainly due to 
increased availability of medical services and earlier diagnosis of colorectal 
carcinoma. 
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Table - 8 
Incidence of conventional and mucinous adenocarcinomas 
Adenocarcinomas No of cases Percentage(%) 
Conventional 
adenocarcinoma 44 88 
Mucinous carcinoma 6 12 
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Table 9 
Histological grades of colorectal adenocarcinomas 
 
Grade No. of Cases 
Grade I 10 
Grade II 33 
Grade III 1 
 
 From above table no.9, it was inferred that Grade II tumours (moderately 
differentiated carcinomas) are more frequent than other grades of colorectal 
carcinomas in this study. 
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Table - 10 
Correlation of age and sex distribution of colorectal carcinoma patients 
with histological grade 
Age Grade I Male Female Total 
21 to 30 0 0 0 
31 to 40 0 2 2 
41 to 50 2 0 2 
51 to 60 3 1 4 
61 to 70 1 1 2 
71 to 80 0 0 0 
Total 6 4 10 
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Table - 11 
Correlation of age and sex distribution of colorectal carcinoma patients 
with histological grade 
Age Grade II Male Female Total 
21 to 30 0 0 0 
31 to 40 3 0 3 
41 to 50 3 7 10 
51 to 60 5 5 10 
61 to 70 2 2 4 
71 to 80 6 0 6 
Total 19 14 33 
 
 
Table - 12 
Correlation of age and sex distribution of colorectal carcinoma patients 
with histological grade 
Age Grade III Male Female Total 
21 to 30 0 0 0 
31 to 40 0 0 0 
41 to 50 0 0 0 
51 to 60 0 1 1 
61 to 70 0 0 0 
71 to 80 0 0 0 
Total 0 1 1 
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Table - 13 
Correlation of age and sex distribution of colorectal carcinoma patients 
with mucinous carcinoma 
Age Mucinous Carcinoma Male Female Total 
21 to 30 0 0 0 
31 to 40 0 2 2 
41 to 50 0 0 0 
51 to 60 0 0 0 
61 to 70 2 2 4 
71 to 80 0 0 0 
Total 2 4 6 
 
 
 From table no.10-13, it was inferred that low grade tumours i.e. grade I & 
grade II tumours occur more commonly in males. High grade tumours i.e. grade 
III and mucinous carcinomas are commonly seen in females.
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Table-14 
Stage distribution of colorectal carcinomas 
 
Stage No of Cases 
Stage I 17 
Stage II 12 
Stage III 18 
Stage IV 3 
 
 Table no.14 shows that stage III tumours are more when compared to 
other stages in this study. 
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Table - 15 
Correlation of age and sex distribution of colorectal carcinoma patients 
with stage 
Age Stage I Male Female Total 
21 to 30 0 0 0 
31 to 40 3 1 4 
41 to 50 0 2 2 
51 to 60 4 2 6 
61 to 70 1 3 4 
71 to 80 1 0 1 
Total 9 8 17 
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Table - 16 
Correlation of age and sex distribution of colorectal carcinoma patients 
with stage 
Age Stage II Male Female Total 
21 to 30 0 0 0 
31 to 40 0 1 1 
41 to 50 0 2 2 
51 to 60 2 2 4 
61 to 70 1 1 2 
71 to 80 3 0 3 
Total 6 6 12 
 
Table - 17 
Correlation of age and sex distribution of colorectal carcinoma patients 
with stage 
Age Stage III Male Female Total 
21 to 30 0 0 0 
31 to 40 0 1 1 
41 to 50 5 2 7 
51 to 60 2 2 4 
61 to 70 3 1 4 
71 to 80 2 0 2 
Total 12 6 18 
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Table - 18 
Correlation of age and sex distribution of colorectal carcinoma patients 
with stage 
Age Stage IV Male Female Total 
21 to 30 0 0 0 
31 to 40 0 0 0 
41 to 50 0 2 2 
51 to 60 0 1 1 
61 to 70 0 0 0 
71 to 80 0 0 0 
Total 0 3 3 
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Table - 19 
HER2/neu expression in colorectal carcinomas 
S.No Biopsy No. Histological Grade Stage 
HER2/neu 
score 
1 14/16 I III 2+ 
2 451/16 III II 0 
3 1153/16 II III 0 
4 1567/16 II I 0 
5 1571/16 I II 0 
6 1799/16 II IV 0 
7 2368/16 II II 0 
8 2624/16 II III 1+ 
9 2671/16 I III 0 
10 3154/16 II II 2+ 
11 3947/16 II III 2+ 
12 4131/16 II II 0 
13 4147/16 I I 1+ 
14 4719/16 II I 0 
15 115/17 MUCINOUS CARCINOMA III 3+ 
16 289/17 II III 0 
17 530/17 II III 2+ 
18 587/17 MUCINOUS CARCINOMA III 0 
19 694/17 II IV 0 
20 706/17 II I 2+ 
S.No Biopsy No. Histological Grade Stage 
HER2/neu 
score 
21 1059/17 II II 0 
22 1185/17 I II 0 
23 1342/17 MUCINOUS CARCINOMA III 1+ 
24 1591/17 II III 0 
25 1684/17 II III 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table - 20 
HER2/neu expression in colorectal adenocarcinomas 
 
HER2/neu 
Expression Positive Negative Total 
Conventional 
adenocarcinomas 5 17 22 
Mucinous 
carcinomas 1 2 3 
Total 6 19 25 
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Table - 21 
HER2/neu scoring in colorectal carcinomas 
Adenocarcinomas HER2/neu score Total 0 1 2 3 
Conventional 
adenocarcinomas 15 2 5 0 22 
Mucinous 
adenocarcinomas 1 1 0 1 3 
Total 16 3 5 1 25 
 
 In this study, HER2/neu expression of moderate membranous positivity 
(2+) and strong membranous positivity (3+) was considered as positive. From 
above table no.20 and 21, it was inferred that, HER2/neu overexpression was 
seen in 6 cases. Among them, five cases showing moderate membranous 
positivity (2+) were conventional adenocarcinomas and one case showing 
strong membranous positivity (3+) was mucinous carcinoma. However 
statistical analysis did not prove this association(p=0.114).
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Table - 22 
HER2/neu expression in colorectal carcinomas in relation to histological 
grade 
Histological 
Grade 
HER2/neu score Total 0 1 2 3 
I 3 1 1 0 5 
II 11 1 4 0 16 
III 1 0 0 0 1 
Total 15 2 5 0 22 
  
 From table no.22, among five cases showing moderate membranous 
positivity (2+) for HER2/neu expression, four cases were grade II tumours 
(moderately differentiated carcinoma) and one case was grade I tumour (well 
differentiated carcinoma). p-value for this finding was 0.414 which was not 
statistically significant. 
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Table - 23 
HER2/neu expression in colorectal carcinoma in comparison with tumour 
stage 
 
Stage 
(AJCC) 
HER2/neu Score Total 0 1 2 3 
I 2 1 1 0 4 
II 6 0 1 0 7 
III 6 2 3 1 12 
IV 2 0 0 0 2 
Total 16 3 5 1 25 
 
 From table no.23, it was evident that strong membranous positivity (3+) 
was observed in one case of stage III tumours and moderate membranous 
positivity (2+) was observed in three cases of stage III tumours and one in each 
of  stage I and stage II tumours. 
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Table - 24 
Correlation of HER2/neu expression in colorectal carcinomas with site of 
tumour 
Site HER2/neu score Total 0 1 2 3 
Caecum 1 0 1 1 3 
Ascending Colon 4 0 0 0 4 
Hepatic Flexure 1 0 0 0 1 
Transverse Colon 0 1 0 0 1 
Descending Colon 0 0 0 0 0 
Sigmoid Colon 4 2 1 0 7 
Rectum 6 0 3 0 9 
Total 16 3 5 1 25 
 
 p-value was 0.025 which was statistically significant. 
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1342/17  70 Yrs Male 
587/17  70 Yrs Female 
FIGURE -1 
ULCEROPROLIFERATIVE  GROWTH  IN TRANSVERSE COLON 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 2 
POLYPOIDAL   GROWTH IN SIGMOID COLON 
 
 
 
 
 
 
 
 
 
 
 
FIGURE – 3 
WELL  DIFFERENTIATED ADENOCARCINOMA (GRADE- I) SHOWING WELL FORMED GLANDS WITH BASALLY ORIENTED NUCLEI AND WITHOUT SIGNIFICANT STRATIFICATION (100X) 
 
 
 
 
 
 
 
 
 
 
FIGURE – 4 
MODERATELY DIFFERENTIATED ADENOCARCINOMA (GRADE -II) SHOWING COMPLEX AND IRREGULAR TUBULAR PATTERN. NUCLEI ARE HIGHLY ATYPICAL, ELONGATED AND STRATIFIED (100X) 
 
 
 
 
 
 
 
 
FIGURE – 5 
POORLY DIFFERENTIATED CARCINOMA (GRADE – III) SHOWING SOLID SHEETS OF MALIGNANT CELLS WITHOUT GLANDULAR DIFFERENTIATION (100X) 
 
 
 
 
 
 
 
 
 
FIGURE – 6 
MUCINOUS CARCINOMA SHOWING TUMOUR CELLS FLOATING IN MUCIN  POOLS (100X) 
 
 
 
 
 
 
 
 
 
FIGURE – 7 
HER2/neu IMMUNOHISTOCHEMISTRY – HER2/neu SCORE 0+ (100X) 
 
 
 
 
 
 
 
 
 
 
FIGURE – 8 
HER2/neu IMMUNOHISTOCHEMISTRY – HER2/neu SCORE 1+ (100X) 
 
 
 
 
 
 
 
 
 
FIGURE – 9 
HER2/neu IMMUNOHISTOCHEMISTRY – HER2/neu SCORE 2+ (100X) 
 
 
 
 
 
 
 
 
 
 
FIGURE – 10 
HER2/neu IMMUNOHISTOCHEMISTRY – HER2/neu SCORE 3+ (100X) 
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DISCUSSION 
 Colorectal carcinoma is one of the most common cancers. Inspite of the 
improvement in treatment modalities, colorectal carcinoma remains as a leading 
cause of cancer mortality. 
 Since the early 1990s, many research activities have been carried out on 
colorectal cancer. As a result of these researches, the basics of tumour biology 
and colorectal carcinoma pathogenesis have been understood. In most of the 
individuals with colorectal carcinoma, cancer development is mainly due to 
complex interaction between the genetic factors and environmental factors(2). 
 About 85% of tumours of  large intestine are adenocarcinomas. The 
incidence of colorectal carcinoma increases after 50 years of age with peak 
incidence between 60 and 70 years of age (4). In this study, age group of  
patients with colorectal carcinoma ranges from 35 to 75 years and peak 
incidence was found between 40 to 70 years of age.  
In this study, 50 colectomy specimens received in Department of Pathology, 
Thanjavur Medical College, during January 2016 to June 2017 was examined. 
These specimen were obtained from Department of General Surgery and 
Surgical Gastroentrology, Thanjavur Medical College. Adequate clinical details 
were collected for all the cases. Among them, 44 cases were conventional 
adenocarcinomas and 6 cases were mucinous carcinomas. 
 
Table - 25 
S.No Studies Age Range (Yrs) 
1 Soo Kyung nam et al (21) 28 - 93 
2 Won-Suk Lee et al (29) 41 - 87 
3 Manmeet Kaur Gill et al (8) 19 - 88 
4 Ingold heppner et al (24) 16 - 98 
5 Sadia Anwar et al (6) 35 - 80 
6 An Na Seo et al (23) 20 - 95 
7 JinhuaTu et al (26) 17 - 85 
8 Present Study 35 - 75 
 
 
 
 
 
 
 
Table - 26 
S.No Studies Mean Age (Yrs) 
1 Soo Kyung nam et al (21) 60 
2 Won-Suk Lee et al (29) 60.8 
3 Manmeet Kaur Gill et al (8) 53.9 
4 Ingold heppner et al (24) 71 
5 Sadia Anwar et al (6) 57.5 
6 An Na Seo et al (23) 65 
7 JinhuaTu et al (26) 51 
8 Present Study 55.8 
 
 In the present study, age of colorectal carcinoma patients ranges from 35 
- 75 years and mean age is 55.8 years. This was in concordance with the study 
done by Sadia Anwar et al (6)and Manmeet Kaur Gill et al(8) (Table .25& 26) 
 
 
 
Table - 27 
S.No Studies Total Cases Male Female 
1 JinhuaTu et al (26) 878 541 337 
2 An Na Seo et al (23) 539 296 243 
3 Ingold Heppner et al (24) 1645 839 806 
4 Manmeet Kaur Gill et al (8) 40 24 16 
5 Won-Suk Lee et al (29) 94 66 28 
6 Soo Kyung Nam et al (21) 191 103 88 
7 Pappas et al(5) 51 18 33 
8 Present Study 50 27 23 
 
 In the present study, out of 50 colorectal carcinoma patients, 27 cases 
were males and 23 cases were females. Thus, in this study, male preponderance 
was seen among colorectal carcinoma patients. This was in accordance with the 
study done by JinhuaTu et al (26),An Na Seo et al (23), Ingold Heppner et al (24), 
Manmeet Kaur Gill et al (8), Won - Suk Lee et al (29) and Soo Kyung Nam et al 
(21) (Table No.27). 
 Most of the proximal colonic carcinomas remain asymptomatic and 
usually presents at an older age group whereas common complaints of distal 
colorectal carcinomas were change in bowel habits, abdominal pain and 
bleeding per rectum(2).In this study also, altered bowel habits was the chief 
complaint noticed in 70% of patients followed by abdominal pain in 40% of 
patients (Table No.2). 
 Among the tumours of colorectal region, rectal carcinomas are commonly 
encountered in Asians (4). In this study also, the commonest site affected by 
colorectal carcinoma was rectum followed by sigmoid colon and caecum. This 
was encountered in all age groups of patients. 
 
 
 
 
 
 
 
 
 
 
Table- 28 
Location of colorectal carcinoma in different studies  
(expressed in percentage) 
S.No Site Abdul Kareem et al (46) (%) 
Osime et al 
(47) (%) 
Qizilbash et 
al (48) (%) 
Present 
study (%) 
1 Caecum 9 2.63 13.53 16 
2 Ascending Colon 6 2.63 11.28 12 
3 Hepatic Flexure 0 1.32 1.50 4 
4 Transverse Colon 4.5 1.32 4.89 2 
5 Splenic Flexure 0 1.32 2.63 0 
6 Descending Colon 3.6 3.94 6.77 0 
7 Sigmoid Colon 0 7.89 34.21 16 
8 Recto Sigmoid 58.8 0 9.02 0 
9 Rectum 0 78.95 14.28 50 
` Total no of cases 420 76 266 50 
  
 In the present study, out of 50 colorectal carcinomas, 33 were situated in 
the distal colorectal region (sigmoid colon and rectum). Among them, 25 cases 
of colorectal carcinoma were situated in rectum which was the commonest site 
affected (50%). This was in accordance with the study done by Osime U et al 
(47) (Table No.28) 
 The proximal colonic tumours usually present as ulceroproliferative 
growth and distal colorectal tumours commonly present as annular lesion 
resulting in narrowing of lumen(4). 
Table - 29 
Growth Patterns of Colorectal Carcinomas 
S.No Studies Ulceroproliferative (%) Polyp (%) 
Narrowing of 
Lumen(%) 
1 Qizilbash et al (48) 54 28 18 
2 Present Study 74 6 20 
 
 Ulceroproliferative growth was the commonest colonoscopic findings 
found in colorectal carcinoma (2). In the present study, 74% of tumours 
presented as ulceroproliferative growth. This includes both right sided and left 
sided colonic tumours (Table No.3). This was in accordance with the study done 
by Qizilbash et al (48)(Table No.29). There was a correlation between HER2/neu 
expression and configuration which was statistically significant(p=0.013). 
Table - 30 
Studies relating sizes of colorectal carcinoma 
S.No Studies Upto 5Cm More than 5Cm Total 
1 JinhuaTu et al (26) 445 433 878 
2 Present Study 32 18 50 
 In this present study, out of 50 cases of colorectal carcinoma, 32 cases 
had tumour size less than 5cm size  (Table No.6). This correlates with the study 
by JinhuaTu et al (26) (Table No.30). Since nowadays, many medical camps and 
screening facilities are available for the patients, their earlier detection of 
colorectal carcinoma may be the reason behind this less tumour size i.e.less than 
5cm size. 
 
 
 
 
 
 
Table - 31 
Incidence of mucinous and non-mucinous adenocarcinoma 
S.No Studies 
Total no. of 
cases in 
study 
Mucinous 
carcinoma 
Non-mucinous 
adenocarcinoma 
No. of cases % No. of cases % 
1 Abdul Kareem et al (46) 405 45 10.7 360 89.3 
2 Osime et al (47) 76 4 5.2 69 90.7 
3 Qizilbash et al (48) 266 14 5 244 91.7 
4 Fazeli et al (49) 403 71 17.6 332 82.4 
5 Present study 50 6 12 44 88 
  
 Mucinous carcinomas constitutes about 10-15% of adenocarcinomas of 
colorectal region. About 85% of tumours of colorectal region were conventional 
adenocarcinomas(2). In this present study, about 12% of tumours were mucinous 
adenocarcinomas and remaining 88% of tumours are conventional 
adenocarcinomas. This was similar to the findings of Abdul Kareem et al (46) 
(Table No.31). 
 Most of the mucinous carcinoma present at advanced stage of disease (15). 
In present study, out of 6 cases of mucinous carcinoma, 4 cases presented at 
stage III disease and one case presented at stage II disease. The 5 year survival 
rate of mucinous carcinomas are estimated to be 43.1% whereas 5 year survival 
rate of conventional adenocarcinomas was estimated to be 79.4% when 
presented at stage II and stage III(50). 
Table - 32 
Comparison of histological grades of adenocarcinoma 
S.No Studies 
Grade I Grade II Grade III 
Total No.of cases % No.of Cases % No.of cases % 
1 Pappas et al (7) 4 7.8 43 84.3 4 7.8 51 
2 Ingold Heppner et al (24) 46 2.9 1253 78.5 298 18.7 1597 
3 Won - Suk Lee et al (29) 37 39.4 53 56.4 4 4.2 94 
4 Manmeet Kaur Gill et al (8) 16 40 13 32.5 2 5 40 
5 Present study 10 20 33 66 1 2 50 
 
 In this study, 33 cases of 50 colorectal carcinoma are moderately 
differentiated carcinomas (Grade II tumours). This correlates with the study 
done by Pappas et al (7), Ingold Heppner et al (24), Won-Suk Lee et al (29) (Table 
No.32). In the present study, Grade II tumours are most common followed by 
Grade I tumours (well differentiated carcinomas). 
Table  - 33 
Comparison of TNM staging of adenocarcinoma in various studies 
S.No Studies 
Stage I Stage II Stage III Stage IV 
Total No.of cases % No.of Cases % No.of cases % No of cases % 
1 Ingold Heppner et al(24) 346 21.0 546 33.2 567 34.5 186 11.3 1645 
2 JinhuaTu et al (26) 12 1.36 174 19.8 648 73.8 44 5.01 878 
3 An Na Seo et al (23) 46 12.6 118 32.3 135 37.0 66 18.1 365 
4 Fazeli et al (44) 33 8.2 193 48.1 134 33.04 41 10.2 401 
5 Present study 17 34 12 24 18 36 3 6 50 
 
 In this study, 18 cases of 50 colorectal carcinomas presented at stage III 
which was more frequent. This was similar to the results of Ingold Heppner et al 
(24), JinhuaTu et al (26) and An Na Seo et al (23). (Table No.33). 
HER2/neu expression in colorectal carcinomas 
 In the present study, 25 cases of 50 colorectal carcinoma cases were 
selected for HER2/neu immunohistochemistry.  
Table - 34 
S.No Studies HER2/neu expression (%) 
1. Pappas et al (5) 3.9 
2 Nathanson et al (30) 3.6 
3 Kavanagh et al (31) 10 
4 Park et al (32) 47.4 
5 Schuell et al (34) 4 
6 JinhuaTu et al (26) 11.6 
7 Li et al (42) 15.5 
8 Lazaris et al (43) 15.5 
9 Kim et al (38) 0.5 
10 Present study 12 
 In this study, 12% of colorectal carcinoma cases showed HER2/neu 
overexpression. Out of them, 2% (n=1) cases showed strong membranous 
positivity  (3+) and 10% (n=5) cases showed moderate membranous positivity 
(2+) for HER2/neu immunohistochemistry. The percentage of HER2/neu 
expression varied in different studies (Table No.34). This may be due to 
interobserver variability and different scoring system used. In some studies, 
cytoplasmic staining were also considered as positive. 
 In the present study moderate membranous staining (2+) HER2 
expression was detected in five conventional adenocarcinomas and strong 
membranous staining (3+) was detected in one mucinous carcinoma (Table 
no.20). There was no association between HER2/neu expression and 
histological variant of colorectal carcinoma (p=0.114). This was in accordance 
to the study done by Marx et al (39) and Kruszewski et al (37). 
 In this study, out of 5 cases showing 2+ HER2 expression, four cases 
belongs to moderately differentiated tumours (Grade II) and one case belongs to 
well differentiated tumour (Grade I). 3+ HER2 staining was detected in one 
mucinous carcinoma (Table No.21). But, there was no correlation between 
HER2/neu expression and tumour grade (p=0.414). This was not  statistically 
significant. This was similar to the results of Kavanagh et al (31), JinhuaTu et al 
(26), Kruszewski et al (37),  Marx et al (39).  
 In our study, 3+ membranous immunostaining was noticed in one stage 
III tumour and 2+ membranous immunostaining was noticed in three stage III 
tumours and one in each stage I and stage II tumour (Table No.23). But, this 
association was not statistically significant (p=0.228). There was no relationship 
between HER2/neu expression and tumour stage. This was similar to the results 
of Sadia Anwar et al (6), Kavanagh et al (31), JinhuaTu et al (26), Kruszuoski et al 
(37). 
 In this study, one of the proximal colonic tumour (caecum) expressed 
strong membranous immunostaining whereas moderate membranous 
immunostaining was expressed in one proximal colonic tumour and four distal 
colorectal tumours. This association was found to be statistically significant 
(p=0.025). This was in accordance with the study done by An Na Seo et al (23). 
 There was no correlation between HER2 expression and 
clinicopathological parameters like age, sex, clinical presentation, tumour size, 
tumour histology, tumour grade and stage . 
 There was statistically significant association between HER2/neu 
expression and tumour site. Also, there was correlation between HER2/neu 
expression and tumour configuration. 
 Many breast cancer patients have been benifited after the development of 
monoclonal antibody therapy against HER2/neu. This leads to evaluation of  
HER2/neu expression in other tumour types also, since it can be used as a 
therapeutic target. HER2 targeted therapy have been used in metastatic gastric 
cancer and this leads to 37% improvement in survival rate. This leads to 
approval of trastuzumab by United States  Food and Drug Administration for 
patients having HER2 positive metastatic lesions (29). 
 Since HER2/neu expression correlates with poorer prognosis, monoclonal 
antibody therapy like trastuzumab (herceptin) can be used in colorectal 
carcinoma patients with HER2/neu overexpresssion. 
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SUMMARY AND CONCLUSION 
 This was a longitudinal retrospective study carried out in our Department 
of Pathology, Thanjavur Medical College during period of January 2016 
to June 2017. 
 Only resected colectomy specimens which was diagnosed as colorectal 
carcinoma was included in this study. 
 Total number of colorectal carcinoma in the study - 50. 
 All these cases had adequate clinical details and colonoscopic findings 
were noted. 
 Histopathological examination was done to asses the grade and tumour 
invasion. 
 TNM staging was used to assess the stage of colorectal carcinomas. 
 HER2/neu overexpression was evaluated in 25 out of 50 cases using 
immunohistochemistry. 
 Age group of colorectal carcinoma patients ranges from 35 to 75 years of 
age with mean age of 55.8 years. 
 Males are predominantly affected than females. 
 The common presenting complaints was altered bowel habits (70%) 
followed by abdominal pain (40%). 
 74% of colorectal carcinoma present grossly as ulceroproliferative 
growth. 
 Rectum was the commonest site affected followed by sigmoid colon and 
caecum. 
 Conventional adenocarcinoma constitutes 88% of colorectal carcinomas 
whereas mucinous carcinoma constitutes 12%. 
 Grade II tumours (moderately differentiated carcinomas) constitutes 66% 
of conventional adenocarcinomas. 
 Most of the colorectal carcinomas presented at stage III (36%). 
 Low grade tumours were commonly seen in males whereas high grade 
tumours were commonly seen in females. 
HER2/neu OVEREXPRESSION 
 HER2/neu overexpression was noticed in 12% of colorectal carcinoma 
cases which includes moderate membranous staining (2+) in 10% of 
cases and strong membranous staining (3+) in 2% of cases. 
 There was a statistically significant correlation between HER2/neu 
expression with tumour site and configuration. 
 No association was found between HER2/neu expression and other 
clinicopathological variables. This includes age, gender, clinical 
presentation, tumour grade, histological variant and staging. 
 Anti-epidermal growth factor receptor monoclonal antibody therapy like 
trastuzumab can be used in these HER2/neu overexpressed colorectal 
carcinoma patients since they are potential candidates. 
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APPENDIX I 
HAEMATOXYLIN AND EOSIN STAIN 
Preparation of solution: 
HARRIS HAEMATOXYLIN 
Distilled water  -1000ml 
Ammonium alum  -100gm 
Absolute ethyl alcohol -50ml 
Mercuric oxide  -2.5gm 
100g of ammonium alum dissolved in 1000ml of distilled water by 
heating and shaking at 60°c. Add solution of 5 g of haematoxylin in 50 ml of 
ethylalcohol and bring rapidly to boil. When it begins to boil, remove from 
flame and add 2.5g of mercuric oxide. Mix by swirling gently. 
EOSIN STAIN 
Eosin Y  -1gm 
Distilled water -20ml 
95% ethanol  -80ml 
Glacial acetic acid -0.2ml 
Dissolve 1 gm of eosin Y in 20ml of water,add 80 ml of 95 % ethyl alcohol and 
0.2 ml of glacial acetic acid. 
 
 
Procedure: 
1. Bring the sections to water. 
2. Dip in Harris haematoxylin for 15 minutes. 
3. Rinse in tap water. 
4. Differentiate in 1% acid alcohol, 3-4 quick dips. 
5. Wash it in tap water briefly. 
6. Dip in ammonia water or saturated lithium carbonate until the sections 
are blue. 
7. Wash in running tap water for 10-20 minutes. 
8. Stain with eosin for 15 minutes depending on the age of eosin and the 
depth of counter stain. 
9. Rinse in tap water. 
10. Dip in 95% alcohol. 
11. 3 changes in absolute alcohol. 
12. Xylene – 2 changes. 
13. Mount in DPX mountant. 
 
 
  
 
 
APPENDIX II 
IMMUNOHISTOCHEMISTRY 
PREPERATION OF SOLUTIONS 
Tris Buffer Saline (TBS) -0.005M 
Distilled water    -10 litres 
Sodium chloride   -80 gm 
Tris (hydroxymethylamine) -6.05gm 
1 N  Hydrochloric acid -44ml 
Final pH is adjusted to 7.6 with either 1N Hcl or 0.2 M Tris solution 
CITRATE BUFFER SOLUTION  
Trisodium citrate    -2.94gm 
1N Hydrochloric acid   -5 ml 
Distilled water    -1000ml 
Final pH is adjusted to 6.0 with 1N Hcl 
Preparation of gelatine coated slides: 
Chrome alum    -0.05gm 
Gelatin    -0.3 gm 
Distilled water    -100 ml 
 Chrome alum is added to distilled water and then heated to 60°c,gelatine 
is added slowly to heated distilled water. Glass slides are then dipped in this 
solution dried overnight. 
Antigen retrieval: 
 The slides are placed in citrate buffer in the coplin jar and capped. The jar 
is then heated in a 750w domestic microwave oven for 15 minutes. 
Procedure: 
1. Dewax the section in xylene (1/2 hr, 2 changes) and bring section to 
distilled water. 
2. Antigen retrievel using TBS by microwave oven heating. 
3. Cool to room temperature in running tap water for 20 minutes. 
4. Bring the section to TBS for 5 minutes. 
5. Drain and wipe of excess TBS around sections. 
6. Incubate in endogenous peroxidase blocking agent for 15-20 minutes. 
7. Gently wash the slides in TBS for 5 minutes. 
8. Wipe off excess fluid and incubate in power block for 15-20 minutes. 
9. Blot and dry excess power block. 
10. Incubate in primary antibody for 60 minutes. 
11. Repeat steps 4 and 5. 
12. Incubate in super enhancer for 30 minutes. 
13. Repeat steps 4 and 5. 
14. Incubate in secondary antibody for 60 minutes. 
15. Repeat steps 4 and 5. 
16. Incubate in DAB (DiaminoBenzidine) substrate buffer for 2 -10 minutes. 
17. Wash in distilled water, counter stain with haematoxylin,clear in xylene 
and mount with DPX. 
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MASTER CHART 
 
S.No HPE. No. Age Sex BPR ALT BH LOW Site Size Configuration Histology Grade Stage HER2/neu
1 14/16 42 M Y N N RECTUM Up to 5CM POLYP MULTIPLE POLYPOSIS COLON I III 2
2 70/16 43 M N N N RECTUM Up to 5CM ULCERO PROLIFERATIVE MUCIN SECRETING    ADENOCA I III
3 202/16 65 F N Y N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II I
4 451/16 53 F N Y N ASCENDING COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA III II 0
5 553/16 70 F N Y Y HEPATIC FLEXURE Up to 5CM ULCERO PROLIFERATIVE MUCINOUS CARCINOMA I
6 946/16 60 F N Y N CAECUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II II
7 1153/16 50 M N Y N SIGMOID COLON Up to 5CM NAROWING OF LUMEN ADENO CA II III 0
8 1264/16 53 M Y N Y RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II I
9 1321/16 35 M N Y N CAECUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA II I
10 1331/16 45 F N Y N SIGMOID COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA II II
11 1567/16 73 M Y N N RECTUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA II I 0
12 1571/16 70 F N N N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA I II 0
13 1624/16 75 M N Y N ASCENDING COLON 6-10 CM ULCERO PROLIFERATIVE ADENO CA II III
14 1710/16 53 M N Y Y CAECUM Up to 5CM ULCERO PROLIFERATIVE MUCIN SECRETING    ADENOCA I III
15 1754/16 37 M Y N N RECTUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA II I
16 1799/16 55 F N Y N SIGMOID COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA II IV 0
17 1902/16 50 F Y N N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II I
18 2251/16 45 F Y N N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II III
19 2368/16 58 M N Y Y RECTUM >10 CM ULCERO PROLIFERATIVE ADENO CA II II 0
S.No HPE. No. Age Sex BPR ALT BH LOW Site Size Configuration Histology Grade Stage HER2/neu
20 2470/16 50 F Y Y N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II II
21 2624/16 54 M N Y N SIGMOID COLON Up to 5CM POLYP ADENO CA II III 1
22 2671/16 40 F Y Y N RECTUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA I III 0
23 3077/16 53 F Y N N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA I I
24 3154/16 75 M N Y N RECTUM Up to 5CM NAROWING OF LUMEN ADENO CA II II 2
25 3236/16 50 F Y N N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II IV
26 3425/16 60 M N Y Y ASCENDING COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA II II
27 3947/16 60 F N Y N SIGMOID COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA II III 2
28 3969/16 35 F Y Y N RECTUM 6-10 CM ULCERO PROLIFERATIVE MUCINOUS CA II
29 4081/16 53 M N N N CAECUM 6-10 CM ULCERO PROLIFERATIVE MUCIN SECRETING    ADENO CA I I
30 4092/16 70 M Y Y N RECTUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA II I
31 4131/16 75 M N Y N HEPATIC FLEXURE GROWTH >10 CM
ULCERO PROLIFERATIVE ADENO CA II II 0
32 4147/16 55 M N Y Y SIGMOID COLON 6 -10 CM ULCERO PROLIFERATIVE ADENO CA I I 1
33 4314/16 40 F N Y N RECTUM Up to 5CM NAROWING OF LUMEN MUCIN SECRETING ADENO CA I I
34 4320/16 50 F Y N N RECTUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA II I
35 4719/16 60 F N Y N ASCENDING COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA II I 0
36 115/17 40 F N Y N CAECUM Up to 5CM ULCERO PROLIFERATIVE MUCINOUS CA III 3
37 230/17 61 M N N Y CAECUM >10 CM ULCERO PROLIFERATIVE MUCINOUS CA III
S.No HPE. No. Age Sex BPR ALT BH LOW Site Size Configuration Histology Grade Stage HER2/neu
38 289/17 66 M N Y N ASCENDING COLON Up to 5CM ULCERO PROLIFERATIVE ADENO CA II III 0
39 530/17 59 F N Y N RECTUM Up to 5CM NAROWING OF LUMEN ADENO CA II III 2
40 587/17 70 F N Y N SIGMOID COLON 6 -10 CM POLYP MUCINOUS CA III 0
41 694/17 45 F N Y N CAECUM Up to 5CM NAROWING OF LUMEN ADENO CA II IV 0
42 706/17 36 M N Y N CAECUM Up to 5CM NAROWING OF LUMEN ADENO CA II I 2
43 1059/17 75 M N Y N SIGMOID COLON Up to 5CM NAROWING OF LUMEN ADENO CA II II 0
44 1185/17 64 M Y N N RECTUM 6-10 CM ULCERO PROLIFERATIVE ADENO CA I II 0
45 1200/17 46 M N Y N RECTUM 6-10 CM NAROWING OF LUMEN ADENO CA II III
46 1342/17 70 M N Y Y TRANSVERSE COLON >10 CM NAROWING OF LUMEN MUCINOUS CA III 1
47 1591/17 74 M N Y N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II III 0
48 1684/17 47 M N Y N ASCENDING COLON 6-10 CM ULCERO PROLIFERATIVE ADENO CA II III 0
49 1736/17 55 M N Y N RECTUM Up to 5CM NAROWING OF LUMEN ADENO CA II I
50 1984/17 70 F Y N N RECTUM Up to 5CM ULCERO PROLIFERATIVE ADENO CA II I
BPR - BLEEDING PER RECTUM
ALT BH - ALTERED BOWEL HABITS
LOW - LOSS OF WEIGHT
HPE - HISTOPATHOLOGICAL EXAMINATION
